Melatonin Agonist on Hospitalized Patients With Confirmed or Suspected COVID-19
Status:
Not yet recruiting
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
COVID-19 is impacting on health systems in Brazil and worldwide. Reducing the risk of
clinical deterioration and prolonged disease duration in hospitalized patients with COVID-19
may alleviate the burden caused by the pandemic. Melatonin (N-acetyl-5-methoxytryptamine) has
demonstrated antiapoptotic, antioxidative, and anti-inflammatory roles and has been suggested
as a potential protector against organ injuries and even mediate lower mortality rates after
polymicrobial sepsis in animal models. Melatonin agonists may modulate protective effects
against acute lung injury and play a clinical role in individuals with SARS-CoV-2 infection.
The investigators proposed a clinical trial testing the effects of ramelteon 8mg in
hospitalized patients with COVID-19.